With Pfizer's unwanted buyout bid in the past–at least for now–AstraZeneca needs to cheer up some of its shareholders. After all, some top investors in the U.K.-based drugmaker wanted to cash in on the proposed takeover. So, once again, CEO Pascal Soriot is making his case for AstraZeneca's bright future.
written on 17.06.2014